VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has announced the appointment of Raju Willener as chief financial officer, effective immediately. This move comes as the company seeks to bolster its financial leadership and advance its proprietary BiTAC(R) technology platform and oncology pipeline.
Willener brings more than three decades of international financial leadership experience, spanning global capital markets, investment banking, corporate finance, asset management, and strategic leadership. He will report to CEO and Co-Founder Christoph Antz, Ph.D., and is expected to support the company’s capital strategy, strategic opportunities, and continued development of its BiTAC(R) technology platform and oncology pipeline.
Prior to joining VERAXA, Willener served as director of corporate development at Exentis Group AG before being appointed CFO in 2025, where he led M&A initiatives, financial strategy, and key corporate functions. Earlier in his career, he held senior executive and investment positions overseeing areas including corporate finance, capital markets, investor relations, and investment portfolios exceeding CHF 30 billion in assets under management.
The appointment of a seasoned financial executive like Willener is a critical step for VERAXA as it navigates the complex landscape of biotech financing and strategic growth. His extensive background in capital markets and corporate finance will be instrumental in guiding the company’s fundraising efforts and potential partnerships, which are essential for advancing its pipeline of bispecific T cell engagers, bispecific ADCs, and other innovative formats.
VERAXA is building a premier engine for the discovery and development of next-generation antibody-based therapeutics. The company’s proprietary BiTAC(R) formats are designed to harness the power of the immune system to target and eliminate cancer cells. With a suite of transformative technologies and rigorous quality-by-design principles, VERAXA is rapidly advancing its pipeline into clinical development and beyond. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
The addition of Willener to the executive team underscores VERAXA’s commitment to strengthening its financial foundation and strategic capabilities. His leadership will be vital as the company seeks to capitalize on its scientific innovations and bring novel cancer therapies to patients. The appointment is expected to have significant implications for VERAXA’s future growth, as it positions itself to attract investment and forge strategic alliances in the competitive oncology sector.
For investors, the appointment of a CFO with such extensive experience in global capital markets is a positive signal. It suggests that VERAXA is serious about executing its business plan and maximizing shareholder value. The company’s focus on next-generation antibody therapeutics, combined with strong financial leadership, could enhance its attractiveness to potential partners and investors alike.
As VERAXA continues to develop its BiTAC(R) technology platform and expand its oncology pipeline, the guidance of a seasoned financial strategist like Willener will be crucial. His track record of managing large investment portfolios and leading M&A initiatives positions him well to navigate the financial complexities of the biotech industry.
The appointment of Raju Willener as CFO is a strategic move that aligns with VERAXA’s long-term vision. It demonstrates the company’s dedication to building a robust financial infrastructure to support its scientific ambitions. With this new leadership in place, VERAXA is well-positioned to advance its pipeline and potentially deliver transformative therapies to patients in need.
